Type 2 diabetes patients could well be producing insulin but it often does not work properly. That's why most type 2 diabetes drugs are designed to help the patients' insulin to work better.

As what is being offered by an Australian Biotechnology company Dia-B Tech Limited who have tested its insulin sensitising factor known as compound ISF402 and found safe for use in humans.

The Melbourne-based biotech company Dia-B Tech Limited have already tested the drug on animals and have started human trials which so far showed no adverse health effects.

The drug was designed to counteract the effect of type two diabetes by making a patient's own insulin work better by attaching itself to insulin and helps break it down to a more useable form so it can work to lower blood glucose.

Dia-B Tech Limited is expecting the safety trials to be completed by mid-year and then plans to begin a larger trial confirm if the treatment really works.

More than one million Australians are believed to be suffering from type 2 diabetes.

Read the full report (a pdf file).